{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020831","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.325926+00:00","generated_at":"2026-06-15T04:05:12.106326+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Clearside Biomedical Q1 net loss $9.3M; Phase 2b ODYSSEY trial to open Q2 2023","bullets":["Net loss of $9.3M ($0.15 per share) vs $7.6M ($0.13) in Q1 2022.","Cash and equivalents $41.4M; company expects to fund operations into Q2 2024.","R&D expenses flat at $4.5M; G&A down to $3.2M from $3.5M.","Phase 2b ODYSSEY trial of CLS-AX in wet AMD to open enrollment Q2 2023; topline results expected Q3 2024.","Positive safety and duration data from OASIS Phase 1/2a extension study presented at ARVO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020831","json":"https://secwatch.observer/filing/0000950170-23-020831.json","markdown":"https://secwatch.observer/filing/0000950170-23-020831.md","text":"https://secwatch.observer/filing/0000950170-23-020831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/0000950170-23-020831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/clsd-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:05:12.106326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1529cebe98f1c0ee1c6600d9bdb9fdb8aff32c17","claim":"Clearside Biomedical, Inc. reported the first quarter ended March 31, 2023 results: revenue $4,000, net income $9.3 million, EPS $0.15 per share.","evidence_excerpt":"First Quarter 2023 Financial Results • License Revenue: Clearside’s license and other revenue for the first quarter of 2023 was $4,000, compared to $347,000 for the first quarter of 2022. • Research and Development (R&D) Expenses : R&D expenses for the first quarter of 2023 and the first quarter of 2002 were $4.5 million. • General and Administrative (G&A) Expenses : G&A expenses for the first quarter of 2023 were $3.2 million, compared to $3.5 million for the first quarter of 2022. • Other Income: Other income for the first quarter of 2023 was $492,000, compared to $2,000 for the first quarter of 2022. Other income in both periods was comprised of interest income from cash and cash equivalents. • Other Expense : Non-cash interest expense for the first quarter of 2023 was $2.2 million, compared to $0 in the first quarter of 2022. Non-cash interest expense was comprised of imputed interest on the liability related to the sales of future royalties and the amortization of the associated i","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023020831/0000950170-23-020831-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$4,000"},{"label":"Net income","value":"$9.3 million"},{"label":"EPS","value":"$0.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}